Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH.
DIFICID vs SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
200 mg (tablet) orally twice daily for 10 days.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Category C
Category D/X
Antibiotic
Antibiotic